Literature DB >> 16732089

Preparation and anesthetic properties of propofol microemulsions in rats.

Timothy E Morey1, Jerome H Modell, Dushyant Shekhawat, Todd Grand, Dinesh O Shah, Nikolaus Gravenstein, Susan P McGorray, Donn M Dennis.   

Abstract

BACKGROUND: The lipophilicity of propofol has required dispersion in a soybean macroemulsion. The authors hypothesized that the anesthetic properties of propofol are preserved when reformulated as a transparent microemulsion rather than as a turbid macroemulsion and that the dose-response relation can be selectively modified by altering the microemulsion's surfactant type and concentration.
METHODS: Microemulsions of propofol were formulated using purified poloxamer 188 (3%, 5%, 7%), and sodium salt of fatty acids (C(8), C(10), C(12)) in saline and characterized using ternary/binary diagrams, particle sizing, and stability upon dilution. Rats received propofol (10 mg . kg(-1) . min(-1)) as either a microemulsion or a conventional macroemulsion to determine these end points: induction (dose; stunned; loss of lash reflex, righting reflex, withdrawal to toe pinch) and recovery (recovery of lash, righting, withdrawal reflexes). After a 14-day recovery period, rats were crossed over into the opposite experimental limb.
RESULTS: Forty-eight microemulsions (diameter, 11.9-47.7 nm) were formulated. Longer carbon chain length led to a marked increase in the volume of diluent necessary to break these microemulsions. All rats experienced anesthetic induction with successful recovery, although significantly greater doses of propofol were required to induce anesthesia with microemulsions irrespective of surfactant concentration or type than with macroemulsions. The sodium salt of C10 fatty acid microemulsion required the greatest dose and longest time for anesthetic induction.
CONCLUSION: Propofol microemulsions cause induction in rats similar to that from macroemulsions. The surfactant concentration and type markedly affect the spontaneous destabilization and anesthetic properties of microemulsions, a phenomenon suggesting a mechanism whereby dose-response relation can be selectively modified.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16732089      PMCID: PMC2999672          DOI: 10.1097/00000542-200606000-00013

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  35 in total

1.  Propofol pharmacokinetics and pharmacodynamics assessed from a cremophor EL formulation.

Authors:  S Dutta; Y Matsumoto; W F Ebling
Journal:  J Pharm Sci       Date:  1997-08       Impact factor: 3.534

2.  Pseudomonas cepacia induced septic shock after propofol--a case report.

Authors:  H P Yu; G J Tang; W J Liaw; H W Yien; T Y Lee
Journal:  Acta Anaesthesiol Sin       Date:  2000-03

3.  Pharmacokinetics and pharmacodynamics of propofol in a new solvent.

Authors:  A W Doenicke; M F Roizen; J Rau; M O'Connor; J Kugler; U Klotz; J Babl
Journal:  Anesth Analg       Date:  1997-12       Impact factor: 5.108

4.  Propofol-based anesthesia as compared with standard anesthetic techniques for middle ear surgery.

Authors:  W S Jellish; J P Leonetti; J R Murdoch; S Fowles
Journal:  J Clin Anesth       Date:  1995-06       Impact factor: 9.452

5.  Low pH, caprylate incubation as a second viral inactivation step in the manufacture of albumin. Parametric and validation studies.

Authors:  Anna Johnston; Eric Uren; David Johnstone; John Wu
Journal:  Biologicals       Date:  2003-09       Impact factor: 1.856

6.  Treatment of Local Anesthetic-Induced Cardiotoxicity Using Drug Scavenging Nanoparticles.

Authors:  Timothy E Morey; Manoj Varshney; Jason A Flint; Surender Rajasekaran; Dinesh O Shah; Donn M Dennis
Journal:  Nano Lett       Date:  2004       Impact factor: 11.189

7.  Toward the development of an injectable dosage form of propofol: preparation and evaluation of propofol-sulfobutyl ether 7-beta-cyclodextrin complex.

Authors:  M K Manoj Babu; Tapan N Godiwala
Journal:  Pharm Dev Technol       Date:  2004-08       Impact factor: 3.133

Review 8.  Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience.

Authors:  Karen S Blesch; Ronald Gieschke; Yuko Tsukamoto; Bruno G Reigner; Hans U Burger; Jean-Louis Steimer
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

9.  The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation (Captisol) versus propofol in a lipid formulation (Diprivan): an electroencephalographic and hemodynamic study in a porcine model.

Authors:  Talmage D Egan; Steven E Kern; Kenward B Johnson; Nathan L Pace
Journal:  Anesth Analg       Date:  2003-07       Impact factor: 5.108

10.  Distribution, metabolism, and excretion of a novel surface-active agent, purified poloxamer 188, in rats, dogs, and humans.

Authors:  J Michael Grindel; Ted Jaworski; Olga Piraner; R Martin Emanuele; M Balasubramanian
Journal:  J Pharm Sci       Date:  2002-09       Impact factor: 3.534

View more
  9 in total

1.  Anesthetic properties of a propofol microemulsion in dogs.

Authors:  Timothy E Morey; Jerome H Modell; Dushyant Shekhawat; Dinesh O Shah; Brian Klatt; George P Thomas; Frank A Kero; Matthew M Booth; Donn M Dennis
Journal:  Anesth Analg       Date:  2006-10       Impact factor: 5.108

2.  Pharmacokinetics and pharmacodynamics of a new reformulated microemulsion and the long-chain triglyceride emulsion of propofol in beagle dogs.

Authors:  S-H Lee; J-L Ghim; M-H Song; H-G Choi; B-M Choi; H-M Lee; E-K Lee; Y-J Roh; G-J Noh
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

3.  Propofol emulsion-free drug concentration is similar between batches and stable over time.

Authors:  Robert Damitz; Anuj Chauhan; Nikolaus Gravenstein
Journal:  Rom J Anaesth Intensive Care       Date:  2016-04

4.  Thromboelastographic and pharmacokinetic profiles of micro- and macro-emulsions of propofol in swine.

Authors:  Timothy E Morey; Jerome H Modell; Jorge E Garcia; Michael Bewernitz; Hartmut Derendorf; Manoj Varshney; Nikolaus Gravenstein; Dinesh O Shah; Donn M Dennis
Journal:  Biopharm Drug Dispos       Date:  2010-07       Impact factor: 1.627

5.  Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.

Authors:  Ramola Sane; Rajendar K Mittapalli; William F Elmquist
Journal:  J Pharm Sci       Date:  2013-01-18       Impact factor: 3.534

6.  Novel lipid and preservative-free propofol formulation: properties and pharmacodynamics.

Authors:  François Ravenelle; Sandra Gori; Dorothée Le Garrec; David Lessard; Laibin Luo; Dana Palusova; J Robert Sneyd; Damon Smith
Journal:  Pharm Res       Date:  2007-11-21       Impact factor: 4.200

7.  Design and evaluation of microemulsions for improved parenteral delivery of propofol.

Authors:  Abhijit A Date; Mangal S Nagarsenker
Journal:  AAPS PharmSciTech       Date:  2008-01-19       Impact factor: 3.246

8.  Lipid-emulsion propofol less attenuates the regulation of body temperature than micro-emulsion propofol or sevoflurane in the elderly.

Authors:  Cheol Won Jeong; Jin Ju; Dae Wook Lee; Seong Heon Lee; Myung Ha Yoon
Journal:  Yonsei Med J       Date:  2012-01       Impact factor: 2.759

9.  β1-Blocker improves survival and ventricular remodelling in rats with lethal crush injury.

Authors:  Mengyang Yu; Qi Lv; Jie Shi; Yahua Liu; Haojun Fan; Hui Ding; Ziquan Liu; Juan Cao; Yanhua Gong; Shike Hou
Journal:  Eur J Trauma Emerg Surg       Date:  2020-06-02       Impact factor: 3.693

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.